Diampa not checked

Getz Pharma

FollowEvery change as it happens, and a Monday email
Stage
in other
Next date
Phase 4 trial completes
Trials
20 active
35 in total · 34 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Empagliflozin + Metformin (Diampa™-M): 5mg+500mg, 5mg+850mg, 5mg+1000mg, 12.5mg+1000mg, 12.5mg+500mg, 12.5mg+ 850mg Empagliflozin Alone (Diampa™): 10mg, 25mg”In the company’s words, NCT05164263 on ClinicalTrials.gov
Tested for
Type II Diabetes Mellitus, Efficacy, Self, Safety Issues
Main trialPhase 4
“Study Objective To evaluate the safety and tolerability of Empagliflozin with or without metformin in patients with Type II Diabetes Mellitus in the Pakistani population. Study design Open-label, prospective, observational, single arm, multi-center, post-marketing surveillance study. Sample size The estimated sample size will be n=156. Duration of study 12 months (data lock point will be completion of 6 months' follow-up from the time of last patient's enrollment date) Safety Assessment: Patient will be monitored for Hypoglycemia, Dehydration, Hypotension, Urinary Tract Infections, Fungal…”In the company’s words, NCT05164263 on ClinicalTrials.gov
Other names
Empagliflozin

Other drugs for Type II Diabetes Mellitus

All 128 drugs for Type II Diabetes Mellitus

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials35

TrialPhaseCompletesWhat it tests
Phase 4Recruiting 31 Dec 2026 Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study
Phase 4Ended not given The effect of empagliflozin on peripheral microvascular dysfunction in heart failure with preserved ejection fraction
Phase 3/4Ended not given Initiation of angiotensin receptor-neprilysin inhibitor (ARNi) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with heart failure with reduced ejection fraction (HFrEF): the INITIATE-HFrEF randomized open-label trial
Phase 3Authorised not given Effect at 3 months of early empagliflozin initiation in cardiogenic shock patients on mortality, rehospitalization, left ventricular ejection fraction and renal function. A randomized multicentric open trial. (EMPASHOCK)
Phase 2Ended not given Effects of empagliflozin on plasma glucose in patients with HNF1A-MODY: a randomized, double-blind, crossover trial
Phase 4Ended not given EMPagliflozin after Aortic Valve Replacement - the EMPAVR study - a randomized clinical trial
Phase 4Authorised not given Study of Empagliflozin in Patients with Autosomal Dominant Polycystic Kidney Disease
Phase 1Ended not given Comparative Bioavailability of Empagliflozin 25 mg Film-Coated Tablets: A Single-Dose, Open-Label, Randomized, Two-Sequence, Two-Treatment, Two-Period Crossover Study in Healthy Subjects Under Fasting Conditions.
Phase 4Ended not given Optimization of Albuminuria-Lowering Therapies for Individual Patients with Type 2 Diabetes Using Empagliflozin and Finerenone in a Pilot Remote Clinical Trial
Phase 2Ended not given Effect of the SGLT2 inhibitor empagliflozin in patients with euvolemic and hypervolemic hyponatremia – a multicentric randomized double-blind placebo-controlled trial (the EMPOWER Study)
Phase 3Authorised not given COmbiNed eFfIcacy and safety of an eaRly, intensive MAnagement sTrategy with fInerenOne and SGLT2 iNhibitor in patients hospitalized with Heart Failure (CONFIRMATION-HF)
Phase 3Authorised not given BIOmarker driven intensification of cardiovascular RISK factor management in patients with high risk for recurrent cardiovascular EVENTs
Phase 2Ended not given The impact of Empagliflozin on Left atrIal Volume and the feasibility of using Fitbit and mHealth to prescribe Exercise in non-diabetic Pre- Heart Failure (ELIVE pre-HF Study)
Phase 2Ended not given Evaluation of the efficacy and safety of empagliflozin in the treatment of neutropenia in patients with glycogenosis Ib. EMPAtia.
Phase 2Authorised not given Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes: A Randomized Open Intervention Study That Compares Empagliflozin, Pioglitazone and Semaglutide (DiaSpax)
Phase 2Ended not given Acute effects of SGLT2 inhibitor on kidney allograft oxygen tension: A randomized, double-blind, placebo controlled crossover trial
Phase 4Authorised not given Acetazolamide in combination with SGLT2i in patients with volume overload and acute heart failure
Phase 3Authorised not given A Phase 3, Randomized, Double-blind, Placebo-controlled Study to evaluate Efficacy and Safety of Empagliflozin in the prevention of Cardiotoxicity in Cancer patients undergoing Chemotherapy based on Anthracyclines (EMPACT study)
Phase 2Halted not given Proof-of-concept study of Empagliflozin in patients with pulmonary arterial hypertension (EmPAH)
Phase 3Ended not given The use of empagliflozin in patients with hypertrophic cardiomyopathy
Phase 3Authorised not given Effects of continued administration of empagliflozin in patients with heart failure on active SGLT2 inhibitor treatment admitted for acute decompensated heart failure
Phase 4Authorised not given Reducing Non-Alcoholic Steatohepatitis
Phase 3Authorised not given EMpagliflozin and daPAgliflozin in patients hospiTalized for acute decompensated Heart failure (EMPATHY) – a phase III Trial
Phase 4Ended not given Intraclass safety and efficacy comparison among SGLT-2 inhibitors in elderly patients with type 2 diabetes. A pragmatic, phase IV, multicenter, open-label, randomised controlled trial.
Phase 3Authorised not given Prevention of cardiac surgery-associated acute kidney injury through the use of sodium-glucose cotransporter 2 inhibitors
Phase 4Authorised not given Pharmacological optimization in prevention in Heart Failure: A Sex-gap? (PopS-HF Trial)
Phase 4Ended not given Open-label, double-arm, controlled, randomized, multicentre clinical trial to evaluate the impact of pharmacogenetic-guided treatment in patients with insufficiently controlled type 2 diabetes
Phase 4Ended not given SGLT-2i, Heart, Improvement of Cardiovascular Autonomic Neuropathy
Phase 3/4Authorised not given Withdrawal of neurohormonal therapy in patients with non-ischemic cardiomyopathy, no late gadolinium enhancement, and negative genetic testing, who have exhibited super-response to cardiac resynchronization therapy. DRUGLESS-CRT clinical trial.
Phase 3Authorised not given Effect of Empagliflozin in patients with eGFR between 10 and 20 ml/min/1.73m2 - EMPA [10-20]
Phase 4Authorised not given A prospective, randomized, controlled clinical pilot trial investigating the partial down-titration of guideline-directed medical therapy in patients with heart failure in remission
Phase 3Authorised not given Sodium-glucose cotransporter-2 inhibitors to stABiLizE coronary atherosclerosis pro-gression after acute Myocardial Infarction in women and men with diabetes mellitus
Phase 4Authorised not given Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery: Impact on Postoperative Cardiovascular Outcomes – DISCO Study
Phase 3Authorised not given A phase III, randomized, prospective, double-blind, parallel design, multi-arm, multicenter study to compare the efficacy and safety of alogliptin and empagliflozin combination therapy versus alogliptin alone and empagliflozin alone in metformin-treated participants with type 2 diabetes mellitus and insufficient glycemic control despite diet and exercise (ODISSEIA 2026).
Phase 2/3Authorised not given The GranStone Trial - Prevention of Kidney Stones due to Paraffin Oil Induced Granuloma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Diampa

Following is part of Solo: you see every change to Diampa the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in